Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a note issued to investors on Thursday. The firm set a "buy" rating on the biotechnology company's stock.

A number of other research firms have also commented on ADAP. Jones Trading lowered shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. Guggenheim lowered their target price on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. HC Wainwright cut their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wells Fargo & Company reduced their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Finally, Scotiabank lowered their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday, March 21st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $1.83.

Adaptimmune Therapeutics Price Performance

Adaptimmune Therapeutics stock opened at $0.30 on Thursday. The stock has a market cap of $77.17 million, a P/E ratio of -1.36 and a beta of 2.86. The company's 50-day moving average price is $0.31 and its two-hundred day moving average price is $0.53. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. As a group, analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Long Focus Capital Management LLC boosted its holdings in Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock worth $11,040,000 after buying an additional 7,194,503 shares during the period. Two Seas Capital LP purchased a new position in Adaptimmune Therapeutics during the fourth quarter worth $7,992,000. Renaissance Technologies LLC raised its position in Adaptimmune Therapeutics by 52.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after purchasing an additional 869,949 shares during the period. Rock Springs Capital Management LP lifted its stake in shares of Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after acquiring an additional 58,000 shares during the last quarter. Finally, Jane Street Group LLC grew its position in Adaptimmune Therapeutics by 87.7% in the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after acquiring an additional 152,780 shares during the last quarter. Institutional investors own 31.37% of the company's stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.